The publication of this webinar was supported by Scholar Rock Inc. This webinar reflects the opinions of the speakers and not necessarily those of its funder, Scholar Rock Inc., or EMJ, and is intended for healthcare professionals. Scholar Rock Inc. were not involved in the development of this content beyond a medical accuracy review.
Disclosures: Ho has received research funding as site investigator from Seelos, Calico, Denali, Biogen, Transposon, Sanofi, the Neurodegenerative Alzheimer’s Disease and Amyotrophic Lateral Sclerosis Basket Trial, VectorY, Neurizon, and Genentech, and compensation for serving on advisory board for Sanofi, Alexion, Biogen, Genentech and Scholar Rock. Monduy has received speaker fees for Catalyst pharmaceuticals, and honoraria for participation in advisory boards for ITF, Catalyst and Sarepta Therapeutics.
Delve into this discussion between featured neurologists Doreen Ho and Migvis Monduy as they explore the role of muscle in spinal muscular atrophy and the unmet needs driving changing landscape of disease management.
Timestamps:
02:15 – Section 1: The pathophysiology of SMA
11:11 – Section 2: Current therapeutic approaches and unmet needs
20:40 – Section 3: The future outlook of SMA
Speakers
Doreen Ho1
Migvis Monduy2
1. Adult Neurologist, Massachusetts General Hospital, Boston; Harvard Medical School, Boston, Massachusetts, USA
2. Paediatric Neurolgist, Cerebral Palsy and Neuromotor Comprehensive Care Center, Nicklaus Children’s Hospital, Miami, Florida, USA
